Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia ; volume:35 ; number:11 ; day:11 ; month:10 ; year:2021 ; pages:1189-1205 ; date:11.2021
CNS drugs ; 35, Heft 11 (11.10.2021), 1189-1205, 11.2021
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-021-00861-6
- URN
-
urn:nbn:de:101:1-2022010719122307675061
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kane, John M.
- McEvoy, Joseph P.
- Correll, Christoph U.
- Llorca, Pierre-Michel
- SpringerLink (Online service)
Ähnliche Objekte (12)
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Controversies Surrounding Quality Measurement in Colon and Rectal Surgery
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic
Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Controversies Surrounding Quality Measurement in Colon and Rectal Surgery
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic
Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Controversies Surrounding Quality Measurement in Colon and Rectal Surgery
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic